{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-23-007072","form_type":"8-K","ticker":"SANA","cik":"0001770121","company_name":"Sana Biotechnology, Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.476741+00:00","generated_at":"2026-06-15T13:52:02.039363+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sana Biotechnology Q1 net loss $82.1M; advancing SC291 trial with data expected H2 2023","bullets":["Cash $355.1M, supports operations into 2025; non-GAAP operating cash burn $74.8M for Q1.","SC291 Phase 1 ARDENT trial enrolling; granted Fast Track for r/r large B-cell lymphoma and CLL.","Plan to file INDs for SC262 and SG299 in H2 2023; SC451 IND in 2024.","Appointed Dr. Doug Williams as President of R&D and Dr. Gary Meininger as CMO.","Net loss $82.1M ($0.43/share) vs $31.4M ($0.17) prior year; R&D expense $67.2M down 7.6%."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-23-007072","json":"https://secwatch.observer/filing/0001564590-23-007072.json","markdown":"https://secwatch.observer/filing/0001564590-23-007072.md","text":"https://secwatch.observer/filing/0001564590-23-007072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770121/000156459023007072/0001564590-23-007072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770121/000156459023007072/sana-8k_20230508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T13:52:02.039363+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f27010c82e2271bd0f3269da1f8b057430427ca","claim":"Sana Biotechnology, Inc. reported financial results for the quarter and year ended March 31, 2023.","evidence_excerpt":"On May 8, 2023, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770121/000156459023007072/0001564590-23-007072-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}